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In recent years, advances in next-generation sequencing (NGS) technology have provided 
the opportunity to detect putative genetic drivers of disease, particularly cancers, with 
very high sensitivity. This knowledge has substantially improved our understanding of 
tumor pathogenesis. In hematological malignancies such as acute myeloid leukemia and 
myelodysplastic syndromes, pioneering work combining multi-parameter flow cytom-
etry and targeted resequencing in leukemia have clearly shown that different classes 
of mutations appear to be acquired in particular sequences along the hematopoietic 
differentiation hierarchy. Moreover, as these mutations can be found in “normal” cells 
recovered during remission and can be detected at relapse, there is strong evidence for 
the existence of “pre-leukemic” stem cells (pre-LSC). These cells, while phenotypically 
normal by flow cytometry, morphology, and functional studies, are speculated to be 
molecularly poised to transform owing to a limited number of predisposing mutations. 
Identifying these “pre-leukemic” mutations and how they propagate a pre-malignant state 
has important implications for understanding the etiology of these disorders and for the 
development of novel therapeutics. NGS studies have found a substantial enrichment 
for mutations in epigenetic/chromatin remodeling regulators in pre-LSC, and elegant 
genetic models have confirmed that these mutations can predispose to a variety of 
hematological malignancies. In this review, we will discuss the current understanding of 
pre-leukemic biology in myeloid malignancies, and how mutations in two key epigenetic 
regulators, DNMT3A and TET2, may contribute to disease pathogenesis.
Keywords: TeT2, Dnmt3a, myelodysplastic syndromes, acute myeloid leukemia, pre-LSC, stem cell biology, 
epigenetic regulator, HSCs
iNTRODUCTiON
One striking finding from NGS studies has been the wide range in the number of mutations that 
appear in different tumor types; while some tumors can contain thousands of changes in cod-
ing sequences, such as bladder adenocarcinoma and melanoma, other tumors have a paucity of 
genetic aberrations (1, 2). Hematological malignancies, such as acute myeloid leukemia (AML) and 
myelodysplastic syndromes (MDS), generally fall within this latter category, where it seems that 
only a handful of exome mutations are necessary and sufficient to drive these malignancies (1–5), 
TABLe 1 | examples of somatic mutations identified in AML and MDS.
 AML MDS Protein names
Signal 
transduction 
(Class I)
FLT3 FLT3 Fms-related tyrosine kinase 3
c-KIT KIT proto-oncogene receptor 
tyrosine kinase
N-Ras, 
K-Ras
N-Ras, 
K-Ras
Neuroblastoma and Kirsten Rat 
Sarcoma Viral (V-Ras) Oncogene 
Homolog
JAK2 JAK2 Janus Kinase 2
CBL Casitas B-lineage lymphoma
Transcription 
(Class II)
CEBP α CCAAT/enhancer-binding Protein alpha
IKZF1 IKAROS family zinc finger 1 
RUNX1 RUNX1 Runt-related transcription factor 1 
(or AML1)
PHF6 PHD finger protein 6
Epigenetic 
regulation
TET2 TET2 Ten eleven translocation 
methylcytosine Dioxygenase 2
IDH1/2 IDH1/2 Isocitrate dehydrogenase-1 and -2
DNMT3A DNMT3A DNA methyltransferase 3A
ASXL1 ASXL1 Additional sex combs like 
transcriptional regulator 1
EZH2 EZH2 Enhancer of Zeste Homolog 2
RNA splicing U2AF1 U2 small nuclear RNA auxiliary factor 1
SF3B1 SF3B1 Splicing factor 3b, subunit 1
SRSF2 SRSF2 Serine/arginine-rich splicing factor 2
ZRSR2 Zinc finger (CCCH Type), RNA-binding 
motif, and serine-/arginine-rich 2
Tumor 
suppressor
CDKN2A/B Cyclin-dependent kinase inhibitor 2A
TP53 TP53 Tumor Protein p53
WT1 WT1 Wilms Tumor 1
Other SMC1A Structural maintenance of 
chromosomes 1A
NPM1 NPM1 Nucleophosmin
2
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although these studies cannot rule out that mutations in regula-
tory elements and non-coding regions are the putative causal hits 
in these diseases. Nevertheless, while the low frequency of coding 
mutations in hematological malignancies would suggest that they 
would be simpler to manage clinically and more amenable to 
targeted therapies, clinical trials using selective inhibitors of sup-
posed driver mutations in the bulk tumor population have been 
largely disappointing thus far and have not been able to achieve 
lasting remission (6–14). Intensive chemotherapy regimens with 
stem cell transplantation remain the standard of care (15, 16). 
Additionally, while clinical remission is achieved in a substantial 
proportion of AML cases, most patients will relapse and die from 
their disease. Determining why tumors with such low mutational 
burden are refractory to targeted therapy and why these patients 
relapse so frequently are therefore critical questions in the field.
Hematopoiesis is a complex and plastic differentiation 
system that requires the temporally coordinated expression 
of large cohorts of genes in progressively more differentiated 
hematopoietic stem and progenitor cells [HSPC; reviewed by 
Dick and Lapidot; Doulatov et al. (17, 18)]. These fate decisions 
have empirically been proven to result from the stoichiometry 
between master transcription factors (19–22). Global regulators 
of transcription, such as epigenetic and chromatin remodeling 
complexes, splicing factors, and the core transcription machin-
eries, also play an important upstream role in establishing the 
correct transcriptional landscape to allow for the efficient activa-
tion or repression of target genes. Interestingly, a number of NGS 
studies have identified a growing list of mutations within these 
factors in MDS and AML (Table  1). Both MDS and AML are 
not single diseases, but rather collections of clinically related but 
phenotypically heterogeneous malignancies. MDS are classically 
thought of as a disease of hematopoietic stem cells (HSC), in 
which patients have either marked reductions in blood produc-
tion, at times precipitating into bone marrow failure, significant 
dysplasia in the cells produced, or some combination of both. 
AML are at least eight separate morphological phenotypes 
[French–American–British (FAB) classification system] that 
involve a large expansion of immature blast populations. The 
clinical hallmark of these malignancies is a differentiation block 
and thus substantial defects in the generation of mature erythro-
cytes, platelets, and/or mononuclear cells such as lymphocytes, 
neutrophils, and monocytes. In both AML and MDS, there 
appears to be multiple parallel clones and subclones that undergo 
evolutionary competition during disease progression, producing 
a clonal hierarchy within each patient (5, 23–27). Importantly, 
these clones may have different susceptibilities to treatment 
options and therefore represent important reservoirs during dis-
ease relapse (28–30). Additionally, these diseases are not stagnant 
but continue to evolve over time; this is best exemplified by the 
finding that some patients with MDS will convert to AML over 
the course of their treatment.
One remarkable finding of AML and MDS has been the discov-
ery of mutations that produce very different clinical phenotypes 
even when these mutations occur in the same cell. For instance, 
a mutation in some gene X in HSC could produce bone marrow 
failure as typified by conditions like aplastic anemia or MDS, 
or could produce a blastic like disease of more differentiated 
progenitor compartments as in AML. Furthermore, mutations 
occurring in the bulk tumor population can also frequently be 
found within supposedly “normal” HSPC that are contribut-
ing to multi-lineage differentiation (26, 28, 31). These findings 
have suggested the existence of a theorized pre-leukemic stem 
cells (pre-LSC). These pre-LSC are fundamentally distinct from 
the tumor initiating, CD34+ CD38− leukemia stem cells (LSC 
or leukemia-initiating cells, LIC) described extensively over 
the past two decades (32–34). Pre-LSC, are clones within the 
hematopoietic hierarchy that are not proliferative or dysplatic, 
but are inherently more likely to transform into a frank leuke-
mia at a higher rate than other HSPC clones. These pre-LSC 
contain a limited number of mutations in AML or MDS related 
genes, such as TET2, DNMT3A, or ASXL1, and have qualitative 
changes that make them leukemogenic, this is in stark contrast 
to non-pre-LSC clones in patients with clonal hematopoiesis of 
indeterminate potential (CHIP; see Discussion and Perspectives 
below). Importantly, pre-LSC are thought to contribute to nor-
mal hematopoiesis while slowly accumulating mutations until a 
critical number are reached to produce LSC. These LSC, having 
crossed some threshold, then give rise to MDS or AML while not 
contributing to normal hematopoiesis. Determining the identity 
of the genes required to cross this “leukemic threshold,” know-
ing within which cell they arise, and knowing what order they 
occurred are the critical questions in the field.
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eviDeNCe FOR PRe-LSC iN HUMAN 
MYeLOiD MALiGNANCieS
The possibility of pre-leukemic HSC harboring leukemia-
associated mutations is not novel. In 1987, Fialkow and col-
leagues first identified presumably leukemic clones contributing 
to normal erythropoiesis in acute non-lymphocytic leukemia 
(35). Building on seminal work by Lapidot and colleagues, 
which first established that CD34+ CD38−, but not blasts, from 
AML patients, constituted LSC and could initiate leukemia in 
xenotransplanted mice (36). Hope et  al. (37) further demon-
strated that these xenotransplanted LSC could undergo further 
clonal evolution in these mice, and later studies showed that 
these cells could even produce normal myeloid and lymphoid 
lineages (38). Recapitulating these findings in xenotransplanta-
tion models, Miyamoto et al. found that AML1/ETO transcripts, 
which are generated due to the leukemic translocation t(8:21) 
in AML, are detectable in mature blood cells of all lineages 
even after stable and complete remission (39). Then, in 2012, 
Jan et al. reported a pioneering study in the pre-LSC field using 
flow cytometry and single clone targeted re-sequencing (26). By 
following the frequency and co-occurrence of many mutations 
within the same patient longitudinally during therapy and at dis-
ease relapse, these authors constructed the most detailed maps 
to date describing clonal dynamics in human AML. Moreover, 
by isolating residual “normal” HSC from these patients (defined 
as CD99− TIM3− CD34+ CD38− Lin−), they identified a number 
of mutations in critical epigenetic regulators frequently mutated 
in AML and MDS. The authors proposed a model whereby the 
disease propagating LSC are derived initially from these residual, 
self-renewing HSPCs that harbored primary mutation(s) 
(Figure  1A). These mutations presumably maintained these 
pre-LSC in a “primed” state that was able to expand into AML 
LSC once a driving mutation was acquired. Importantly however, 
these residual pre-LSC but not putative LSC (CD99+ CD34+ 
CD38− Lin− cells) were contributing to normal, multi-lineage 
hematopoiesis, again deviating significantly from prior cancer 
stem cell (CSC) models, whereby the CSC was incapable of gen-
erating normal tissue. Studies previously showing that LSC were 
capable of multilineage reconstitution were presumably assaying 
these same pre-LSC as those studies only used CD34 and CD38 
to enrich for LSC (38).
In addition to providing the best evidence to date for pre-LSC, 
this work and studies by a number of other groups have since 
made the remarkable discovery that the mutations occurring in 
pre-LSC and the bulk tumor were categorically different: while 
early mutations in pre-LSC were frequently in epigenetic and 
chromatin remodeling regulators, driver mutations in myeloid 
transcription factors and signal transduction molecules such as 
tyrosine kinases tended to occur late in bulk blast cells (40, 41). 
This surprising finding not only helped explain why potent tar-
geted therapies for some driver mutations failed to cure patients; 
it also suggested something fundamental about AML biology 
and the order in which mutations were acquired.
Based on these observations, a number of groups started 
investigating how mutation sequence affects clinical outcomes in 
myeloid malignancies. If leukemia did indeed arise from pre-LSC 
harboring mutations that primed cells for leukemogenesis, then 
one would predict that the order within which mutations were 
acquired might influence the clinical phenotype. Ortmann et al. 
(42) tested this hypothesis by determining the mutational order 
between the epigenetic regulator Ten-Eleven Translocation 2 
(TET2) and a putative driver JAK2 V617F. These genes have been 
reported to be mutated in both pre-LSC and fully transformed 
malignant disorders such as the Philadelphia chromosome 
negative myeloproliferative neoplasms (MPN) [such as primary 
myelofibrosis (PMF), essential thrombocythemia (ET), and 
polycythemia vera (PV)], AML, and MDS. In this study, the 
authors focused on the MPNs, ET and PV, where the same JAK2 
mutations are almost universal in both conditions despite very 
different clinical phenotypes, and sought to determine whether 
the order of TET2 and JAK2 mutations along the hematopoietic 
lineage and within malignant clones drove differences in the clini-
cal phenotype of the MPN. They found that the mutation order 
of TET2 and JAK2 V617F influenced the age when the MPN was 
diagnosed, the subclonal composition and proliferative capac-
ity of flow cytometry defined HSPC in these patients, and the 
transcriptional profile of the malignant HSC (42). Similar obser-
vations were additionally reported for DNA Methyltransferase 3 
alpha (DNMT3A) mutations in MPN (43). However, the most 
interesting finding from these studies was that the clinical 
manifestations of disease were also significantly influenced by 
mutational order: acquiring either TET2 or DNMT3A mutation 
prior to the JAK2 mutation resulted in a much higher frequency 
of ET rather than PV.
In recent years, a number of important sequencing studies 
have also established that while hematopoietic clonality can influ-
ence clinical outcomes, identifying clones with certain mutations 
carries much more prognostic information. Two whole-exome 
sequencing studies of peripheral blood mononuclear cells longi-
tudinally tracked clonal hematopoiesis during aging to establish 
whether the presence of clonal hematopoiesis correlated with 
AML development (5, 27). In both studies, the authors found 
that clonal hematopoiesis became more common with older 
age, that patients with clonal hematopoiesis had slightly higher 
rates of AML, and that the most common mutations in these 
clones were in ASXL1, TET2, and DNMT3A. Consistent with 
these results, Yoshizato et  al. found strong evidence in aplastic 
anemia patients that while the degree of clonal hematopoiesis 
was variable and itself not well correlated with overall survival, 
clones harboring mutations in the epigenetic modifiers ASXL1 
and DNMT3A expanded much more rapidly than other clones in 
the same patient and that patients carrying these types of clones 
had significantly poorer overall survival and higher rates of 
transformation to AML (44). Recently, another group described 
the presence of chemotherapy-resistant HSC in patients with 
AML after chemotherapy that appeared to expand rapidly upon 
depletion of the bulk tumor (28). Again, these clones harbored 
mutations in epigenetic modifiers commonly seen in AML 
patients and therefore may represent the expansion of leukemia 
primed pre-LSC in these patients. Finally, Ivey and colleagues 
found that minimal residual disease, which was detected by 
the presence of Nucleophosmin (NPM1)-mutated transcripts in 
normal mononuclear cells after achieving remission in AML, 
FiGURe 1 | Hypothetical model of leukemogenesis in TET2 and DNMT3A mutations (A) Model of the stepwise mutation accumulation during pre-leukemic 
hematopoiesis and leukemogenesis. Numerous studies have suggested that mutations converting HSPC to pre-leukemic stem cell (pre-LSC) are in epigenetic 
regulators and may lead to aberrant transcriptional networks utilized in both HSC self-renewal and differentiation. When additional hits are then acquired in 
these pre-LSC, leukemia develops. Importantly, pre-LSC still contribute to normal hematopoiesis and self-renew similar to normal HSC (indicated in both by 
solid arrows) until malignant transformation (indicated with broken red arrow) in the pre-LSC model. (B) Hypothetical model of CHIP and pre-LSC. CHIP is 
defined as oligoclonal hematopoiesis in the presence of an AML or MDS mutation yet without cytopenia or dysplasia. Pre-LSC are phenotypically normal clones 
harboring mutations in AML and MDS genes, and can occur in CHIP or in non-CHIP patients. The major theoretical difference between pre-LSC and HSC 
participating in CHIP is the propensity to transform once additional hits are obtained. While these hits do not readily transform other CHIP clones, pre-LSC 
clones can rapidly progress to fully malignant state. The qualities that confer this “primed leukemic state” are currently unknown but presumably account for 
why not all patients with CHIP develop AML or MDS, as indicated in the figure. HSPC, hematopoietic stem and progenitor cell; CHIP, clonal hematopoiesis of 
indeterminate potential; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes.
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was one of the strongest predictors of relapse and carried a poor 
overall survival. While this study was not addressing pre-LSC 
mutations per  se, the fact that finding oncogenic transcripts in 
normal mature blood cells after AML remission carried a strongly 
poor prognosis clearly fits well with a model of pre-LSC being 
primed to transform rapidly into relapse AML despite contribut-
ing to normal hematopoiesis (45). Taken together, it appears that 
pre-LSC have qualitative changes that make them distinctly more 
prone to leukemia initiation than other HSC.
DiSCRiMiNATiNG CHiP FROM PRe-
LeUKeMiA
Although the evidence for pre-LSC has garnered substantial 
support owing to the work described above, one question has 
plagued both clinical and translational studies: why do some 
patients with clonal hematopoiesis harboring mutations in MDS 
and AML-associated genes never develop disease? In the stud-
ies by Jaiswal et  al. and Genovese et  al. mentioned above, the 
TABLe 2 | Cell types that associate with leukemoginesis and their cell surface markers.
Cell type Hematopoietic lineage potential Leukemogenic Presence of 
AML/MDS 
mutations?
Cell surface markers
HSC Yes No No Lin-CD34+CD38-CD90+ (39)
Multilineage contribution to all mature 
blood populations, self-renewal
Progenitors Yes No No Many, e.g., GMP: Lin-CD34+CD38+CD45RA+CD123+ (47)
Restricted differentiation potential
LSC No Yes Yes Lin-CD34+CD38-. Many reported markers, CLL-1 (48), CD25 (49), CD32 
(49), CD96 (50), TIM-3 (51, 52), CD99 (52), CD47 (53), IL3RA (54)
pre-LSC Yes Yes Yes Unclear. Reports suggest Lin-CD34+CD38-TIM3-CD99− (52) or Lin-
CD34+CD38-IL1RAP+ (55)Multilineage contribution to all mature 
blood populations, self-renewal No definitive marker available
CHIP Yes Minimal risk Yes Unclear. Presumably same as HSC
Multilineage contribution to all mature 
blood populations, self-renewal
GMP, granulocyte-macrophage progenitor; IL3RA, interleukin 3 receptor; TIM-3, T-cell immunoglobulin and mucin domain 3; IL1RAP, IL-1 receptor accessory protein.
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majority of patients with clonal hematopoiesis harboring muta-
tions in canonical preleukemic mutations (e.g., TET2, ASXL1, 
or DNMT3A) never developed MDS or AML. This realization 
has complicated our understanding of pre-LSC as it suggests that 
preleukemic mutations are not fully sufficient to generate the 
“pre-LSC state” than primes for leukemic transformation. To help 
describe this scenario whereby a patient has limited hematopoi-
etic clonality and harbors preleukemic mutations but does not 
have an increased risk of AML or MDS, a number of translational 
researchers and clinicians have described a clinical entity called 
“clonal hematopoiesis of indeterminate potential,” or CHIP, 
which is analogous to monoclonal gammopathy of unknown sig-
nificance (MGUS). CHIP is defined as oligoclonal hematopoiesis 
without morphological changes or cytopenia, where one or more 
genes typically associated with AML or MDS are mutated. CHIP 
patients have a very low rate of conversion to AML or MDS and 
therefore (and unlike in MDS) can be monitored clinically rather 
than proactively treated. A more detailed description of CHIP, 
the research leading to its characterization, and the diagnostic 
criteria separating it from MDS and AML are discussed exten-
sively by Steensma and colleagues (46) and are beyond the scope 
of this review. While CHIP is clearly different from frank MDS or 
AML, discriminating CHIP from pre-leukemia is nuanced. CHIP 
is a risk classifier that describes, clinically, the probability of a 
patient to develop leukemia. Pre-LSC are cells that deterministi-
cally drive AML or MDS. While CHIP patients absolutely have 
an increased risk for these malignancies, the overall risk is still 
quite low. Pre-LSC, on the other hand, are fundamentally primed 
to contribute to leukemia initiation: according to the current 
model of leukemogenesis, all AML and MDS patients have pre-
LSC that contribute to normal hematopoiesis, the bulk leukemia, 
and relapse. Therefore, all CHIP patients that develop AML 
had a resident pre-LSC clone in their CHIP and it does appear 
that CHIP seems to increase the risk of developing a pre-LSC. 
However, not all patients with CHIP will ever develop a pre-LSC 
and therefore will never develop MDS or AML. Moreover, not 
all AML patients originally had CHIP (Figure 1B). Importantly, 
the qualitative distinction that makes pre-LSC leukemogenic in 
patients with or without CHIP does not need to be genetic: epige-
netic differences, metabolic rates, cell extrinsic influences, or the 
transcriptional context of that particular HSC may discriminate 
what is a primed pre-LSC from a normal HSC that happens to 
harbor an AML associated mutation. As such, exome capture 
alone is unlikely to fully capture why these clones are inherently 
more likely to transform. Unfortunately, as cell surface mark-
ers have not been discovered that unambiguously capture only 
pre-LSC from other HSC or CHIP clones, this model cannot 
be tested empirically at this time (for a more detailed descrip-
tion of the differences between HSC, pre-LSC, CHIP, and LSC, 
along with relevant references, see Table  2). Furthermore, we 
cannot exclude the possibility that all clones in CHIP would, if 
provided enough time, become pre-LSC and generate leukemia; 
it is completely possible (and indeed highly plausible) that this is 
an entirely stochastic process of trait acquisition. Nevertheless, 
irrespective of the difficulties in separating these clinical subtle-
ties with current technology, the evidence outlined above clearly 
shows that pre-LSC are real biological entities. Moreover it is also 
certainly true that the mutations isolated from pre-LSC must have 
a role in transforming pre-leukemic hematopoiesis to AML and 
MDS, as the presence of these mutations absolutely increases the 
probability of leukemogenesis. As noted, studies have repeatedly 
shown that many of these candidate antecedent mutations in 
pre-LSC are in epigenetic regulators. Given these observations, a 
substantial amount of effort has been directed at understanding 
how mutations in epigenetic factors deregulate hematopoiesis 
and precipitate hematological malignancies.
MUTATiONS iN DNA MeTHYLATiON 
ReGULATORS
Since epigenetic modifications regulate genome wide transcrip-
tional profiles and help establish cell-type specific gene expression 
profiles during cell differentiation (56), mutations in these genes 
in HSPC may have profound effects on normal hematopoiesis. 
FiGURe 2 | Diagram of human TET2 and DNMT3A and missense mutations in AML and MDS. The black dots indicate the missense mutation sites (66–71). 
The majority of mutations in TET2 are identified in the two catalytic domains, shown as double-stranded β-helix (DSBH) and Cys-rich domain (64, 72). Magenda, 
green, and blue triangles on TET2 diagram represent the site associated with N-oxalylglycine (NOG, a 2-OG analog), CpG recognition and Fe(II) binding based on 
the crystal structure and biochemical analysis (73, 74). Red dot on DNMT3A indicates the hot spot mutation at R882.
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Two of the best-characterized epigenetic mutations found in 
pre-leukemic HSPC are in DNMT3A and TET2 (Figure  2). 
DNMT3A and DNMT3B are de novo methyltransferases that 
catalyze DNA methylation at target DNA, while DNMT1 is 
responsible for maintenance methylation at the replication folk 
during DNA synthesis (57–59). De novo DNMTs are essential to 
mammalian development (60, 61) as these marks, particularly 
5-methylcytosine (5-mC) in CpG islands, are correlated with 
transcriptional silencing. TET2, conversely, is an enzyme that 
plays a central role in DNA demethylation by catalyzing the con-
version of 5-mC to 5-hydroxymethyl cytosine (5-hmC) (62–64). 
While first discovered in 1972 (65), the functional importance of 
5-hmC was not clear until recently due to the high mutational 
frequency of TET2 in myeloid malignancies (Table 1). We will 
now focus on mutations in these enzymes in MDS and AML to 
shed insight into the role these factors play in hematopoiesis 
and leukemia.
ReGULATiON OF DNMT3A AND iTS 
ROLe iN TRANSCRiPTiONAL CONTROL
DNMT3A is a de novo methyltransferase of DNA and muta-
tions have been isolated in patients with AML (69, 71) and 
MDS (70,  75). DNMT3A mutations frequently co-occur with 
NPM1, FLT3, and IDH1 (76), and overall approximately 20% of 
patients with AML (69, 71) and 8% of patients with MDS (70) 
carry a mutation in this factor. Patients harboring mutations in 
DNMT3A typically have a poorer overall prognosis, although this 
depends significantly on which cooperating mutations co-occur 
in that patient (69–71).
The importance of DNA methylation in determining cell 
identity is well documented, but how de novo methyltransferase 
activity is regulated and how methyltransferases are targeted to 
specific DNA sites remains poorly understood. Recent studies 
have suggested strong cross-talk between histone modifications, 
transcriptional activity, and prior DNA methylation status 
on DNMT localization. Highly conserved PWWP (proline– 
tryptophan–tryptophan–proline) domains in DNMT3A play an 
essential role in directing this factor to heterochromatic regions 
(77, 78), particularly those marked with histone 3 lysine 36 tri-
methylation (H3K36me3), which is a known repressive histone 
modification. Presence of this mark was also reported to increase 
the methyltransferase activity of DNMT3A (79). Protein–protein 
interactions with other factors also appear to play an important 
role in DNMT3A recruitment. DNMT3A has an ADD [ATRX-
DNMT3- DNMT3-like (DNMT3L)] domain, which is a cysteine-
rich (Cys-rich) zinc-finger DNA-binding domain, reported to 
interact with many transcription factors and chromatin remod-
eling factors such as HP1, SUV39H1 (80), EZH2 (81), HDAC1 
(82), p53 (83), Myc (84), and PU.1 (85) (Figure 2). This domain in 
DNMT3A also shows high affinity for unmethylated histone H3 
peptides but not H3 lysine 4 tri-methylated (H3K4me3) peptides 
(86–88), indicating that the ADD may also be involved in chro-
matin reading as well. Interestingly, based on the crystal structure 
of DNMT3A and after biochemical analyses, it was found that the 
ADD participates in an auto-regulatory capacity to effect changes 
in DNMT3A activity: in the absence of histone H3, ADD domain 
binds to the catalytic domain of DNMT3A leading to blocked 
enzymatic function; in the presence of unmethylated H3, the 
ADD binds this H3, allowing the catalytic domain to become 
accessible for de novo DNA methylation catalysis (89).
A final, important regulatory step controlling DNMT3A 
activity is tetramer formation. DNMT3A can exist in a variety 
of tetramer states composed of homo-dimers of DNMT3A or 
hetero-dimers with DNMT3L, which is a catalytically inactive 
protein that enhances the methyltransferase activity of DNMT3A 
(90). While all tetramers are catalytically active, each variant 
tetramer has marked differences in enzyme processivity (91). 
Therefore, understanding the regulation of tetramer formation, 
and specifically determining the mechanisms underlying homo- 
versus hetero-dimerization may be critical to understanding 
the regulation of DNMT3A function. Recent studies have also 
noted that these tetramers are sensitive to pH and decreasing 
pH disrupted the distribution of various tetramers of DNMT3A 
in vitro (91). As different cell types, and notably cancer cells, exist 
at slight variations in pH, destabilization of DNMT3A tetramers 
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due to changes in intracellular pH may represent a relatively 
unexplored mechanism by which DNA methylation patterns are 
deregulated in tumors (92, 93).
DNMT3A MUTATiONS iN AML AND MDS
About 40–60% of DNMT3A mutations in AML patients are a 
hotspot mutation in Arg882 (R882), which is located within the 
catalytic domain of the enzyme (69, 71) (Figure 2). In addition 
to presumably reducing the catalytic efficiency of DNMT3A, 
this hotspot mutation also appears to influence the ability of 
DNMT3A to homodimerize. Normally, DNMT3A functions as a 
tetramer, comprised of either two homodimers or heterodimers 
DNMT3L. While R882 mutations in DNMT3A are still able 
to undergo hetero-dimerization with DNMT3L (94), they are 
unable to homo-dimerize (95, 96), suggesting that the R882 
mutation is a dominant-negative mutation, which interrupts 
tetramer formation leading to the reduction of methyltransferase 
activity. DNMT3A mutations probably were inducing AML by 
leading to passive demethylation of the genome, and some genes 
(e.g., HOXB) have been found to be differentially hypomethylated 
in DNMT3A mutant AML (71). One recent study in murine HSC 
has indicated that many genes deregulated in leukemia, including 
transcription factors, exist in sites termed methylation canyons 
that are prone to methylation loss in the absence of DNMT3A 
(97). These results, however, conflict with whole genome profil-
ing using Methylated DNA IP (MeDIP)-chip analysis and gene 
expression profiling that have thus far found little impact of 
DNMT3A mutations on global methylation patterns and little 
correlation between changes in methylation status and differ-
ential gene expression (69). One possible interpretation of this 
finding is that DNMT3A mutations play a more important role in 
pre-LSC transcriptional changes in HSPC that allow for leukemia 
to develop in more differentiated blasts, and that these changes 
are in effect “averaged-out” with standard ensemble techniques. 
Consistent with this idea is the finding that in inducible mouse 
deletion models of Dnmt3a, HSPC have mild phenotypic changes 
such as impaired differentiation, increased self-renewal, and 
occasionally transform to a myeloproliferative disease, but do not 
show robust changes in DNA methylation patterns or correla-
tion between methylation changes and gene expression profiles 
(98–101). Double knockouts for Dnmt3a and Dnmt3b, however, 
show synergism in their phenotype, suggesting that there may 
exist compensatory activity between the de novo DNMTs in 
murine HSC that reduces the impact of single gene loss (98, 101). 
Moreover, inducible overexpression of Dnmt3b in mice was able 
to significantly slow leukemia induction by both Myc-Bcl and 
Mixed Lineage Leukemia (MLL)-AF9 (102). These findings in 
mice raise an important question as to why DNMT3B mutations 
are so rare in human AML and MDS, indicating that perhaps this 
compensatory pathway is not as robust in human HSC (76).
FUNCTiONAL ROLe OF TeT2 iN 
TRANSCRiPTiONAL ReGULATiON
While 5-hmC-modified DNA was biochemically isolated decades 
ago, it was the recent discovery of TET mutations in AML and 
MDS that prompted further investigation of the functional role 
in these marks, and their writers the TET enzymes, play in tran-
scriptional regulation. TET1 was the first TET family member 
successfully isolated, originally found as a translocation partner 
of MLL gene in AML (103–105). While Ono and colleagues were 
the first to clone the gene and named it LCX (leukemia-associated 
protein with a CXXC domain) (106); Lorsbach et al. (107) cloned 
the same partner of the MLL translocation and named it TET 
for Ten-Eleven Translocation owing to its frequent MLL fusion 
[t(10;11)(q22;q23)] in AML. Three TET enzymes, TET1, 2, and 
3, have since been identified (107).
All three TET enzymes convert 5-mC to 5-hmC, which is 
later converted to 5-formylcytosine (5-fC) and then 5-carboxyl-
cytosine (5-caC) (62–64). While each enzyme is capable of 
catalyzing these reactions, expression profiling has shown cell 
type distribution differences between the different TET enzymes, 
indicating distinct functions or regulators (62). Classically, 
conversion of 5-mC to 5-hmC at promoters and transcription 
start sites (TSS) would be predicted to lead to transcriptional 
activation by eliminating DNA methylation, which is correlated 
with transcriptional repression at CpG islands. Williams et  al. 
(108), however, reported an unexpected role for TET1 as a 
transcription repressor in embryonic stem cells. Moreover, 
other groups have found that TET1, but not TET2, interacts 
with the transcriptional repressive histone deacetylase SIN3A 
(108, 109). While TET2 is still typically believed to be involved 
in transcriptional activation, these non-canonical activities of 
other TET family members at least leaves open the possibility 
that TET2 may have as of yet unidentified regulatory roles in 
transcription. One recent finding is that TET2 can regulate 
histone O-acetylglucosaminylation (O-GlcNAcylation) of serine 
and threonine residues of histone 2B (H2B), which is reported to 
associate with active transcription at TSS (110). Chen et al. (111) 
found that TET2 regulates these levels indirectly by recruiting 
via its catalytic C terminus O-GlcNAc transferases (OGT) to tar-
get loci. Importantly, this interaction does not affect the 5-hmC 
catalytic activity of TET2 (111–113).
ReGULATORS OF TeT ACTiviTY
While different cell types seem to express different amounts of 
each TET enzyme, it has become clear that post-translational 
regulation is critical in controlling TET activity and targeting to 
genetic loci. All TET enzymes contain one Cys-rich domain and 
two double-stranded β-helix (DSBH) domains that display the 
core catalytic domains, which act in a Fe(II) and 2-oxoglutarate 
(2-OG, also called as α-ketoglutarate) dioxygenases-dependent 
manner (73). Mono ubiquitinylation at a conserved lysine residue 
(residue 1299 in TET2) (114, 115) or binding of ascorbic acid 
in this catalytic domain directly facilitates TET catalytic activ-
ity by stabilizing Fe(II) association with the enzyme (116, 117) 
(Figure 2).
Targeting of TET2 to genomic regions was initially unclear as 
TET2, unlike TET1 or TET3, does not possess a canonical CXXC 
domain that binds unmethylated CpG. Ko et al. (118) then found 
an ancestral variant of the CXXC domain, referred to as IDAX 
(a.k.a. CXXC4) 650 kb upstream of TET2, which appears to have 
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been separated from the TET2 coding region by chromosome 
inversion during evolution. IDAX interacts with unmethylated 
CpG DNA in vitro similar to the canonical CXXC domain (118). 
Genomic distribution of IDAX as determined by Chromatin IP 
(ChIP) showed that about 40% of IDAX peaks were enriched 
in the promoter/TSS, which suggested that IDAX acted as a 
cofactor to recruit TET2 to target sites. Unexpectedly, however, 
overexpression of IDAX actually reduced the global level of 
5-hmC (118), despite finding no changes in the TET2 mRNA 
levels. Additionally, while the variant CXXC domain of IDAX 
was able to directly associate with the catalytic domain of TET2, 
IDAX does not block TET2 enzymatic activity directly. Instead, 
it appears that IDAX destabilizes the TET2 protein, which is then 
degraded through caspase 3 and 8 (118).
An important regulatory control on TET activity has been 
recently discovered with the finding of Isocitrate Dehydrogenase-1 
and -2 (IDH1/2) mutations in a variety of tumors, including 
AML and MDS. IDH1/2 are enzymes that play an important 
role in the tricarboxylic acid cycle (TCA). Heterozygous, gain of 
function mutations in these enzymes have been found in high 
frequency in myeloid malignancies (119, 120). These mutations 
cause IDH1/2 to produce an oncometabolite, 2-hydroxyglutarate 
(2-HG), instead of 2-OG (121). This is a competitive antagonist 
of 2-OGT enzymes, which in turn leads to severely reduced TET 
enzyme activity. As predicted, Figueroa et  al. (122) found that 
IDH1/2 mutations in AML patients lead to genome wide DNA 
hypermethylation signatures. While the population of patients 
with genetic IDH1/2 mutations does not overlap with TET2 
mutations, these different mutations have essentially synonymous 
hypermethylation signatures. This suggests that IDH1/2 and 
TET2 mutations phenocopy one another and therefore do not 
confer additional selective advantages during clonal evolution in 
these diseases.
TET2 MUTATiONS iN AML AND MDS
Loss of functional TET2 has been extensively reported in both 
AML and MDS. In addition to translocation fusions with MLL, 
DNA FISH studies have shown that TET2 is frequently deleted in 
both malignancies (123). TET2 mutations have been identified 
in 12–24% of AML patients and 7–26% of MDS patients (66–68). 
Most mutations in TET2 are heterozygous and the presence of 
mutations carries a poor prognosis in either malignancy (66). 
Missense mutations of TET2 in AML and MDS patients are 
commonly located in the catalytic domain, spacer region, or 
the Cys-rich domain (Figure 2), or were nonsense or frameshift 
mutations. Notably, as many of these mutations can be found 
in flow cytometry defined HSC or early progenitor cells from 
patients with AML or MDS, TET2 mutations are hypothesized to 
be possible pre-leukemic mutations (67, 68, 124).
A number of recent studies have focused on delineating the 
functional role TET2 plays in hematopoiesis. First, expression of 
TET2 with mutations at its predicted Fe (II) and 2-OG binding 
residues led to decreased 5-hmC levels in cell lines compared to 
expression of wild-type enzyme, suggesting that the common 
mutations in these residues occurring in AML are loss of func-
tion. Loss of TET2 has important phenotypic consequences in 
hematopoiesis. Transduction of TET2 shRNA in bone marrow 
stem/progenitor cells impaired myelopoiesis (73), while both 
germline and conditional knockout of Tet2 in mice in HSC 
leads to granulomonocytic (GM) lineage skewing at the expense 
of the erythroid and lymphoid lineages, as well as increased 
5-mC level and decreased 5-hmC (125–127). Additionally, loss 
of TET2 in human CD34+ cord blood recapitulates findings in 
mice, with differentiation skewing along GM lineages in ex vivo 
culturing conditions, along with increased HSPC self-renewal 
(128). To summarize, in both mouse and human models, TET2 
loss appears to promote GM lineage skewing and increases the 
self-renewal capacity of HSPC with aberrant ratios between 
5-mC and 5-hmC.
The detailed mechanism of how TET2 mutations propagate 
leukemic and pre-leukemic states in myeloid malignancies 
remains poorly understood. As expected, many studies reported 
that TET2 mutations or depletion resulted in decreased 5-hmC 
globally (73, 125, 128). While the functional importance of 
DNA methylation at CpG islands has been correlated with 
transcription silencing, it appears that demethylation reac-
tions catalyzed by TET2 might be more nuanced. Specifically, 
it was found by Ko et  al. (73) that DNA hypermethylation 
profiles in bone marrow samples from patients harboring 
TET2 mutations was enriched predominantly in non-CpG 
sites, while CpG islands were actually hypomethylated. Other 
groups have confirmed that the hypermethylation phenotype 
of TET2 mutations appears to be principally outside of CpG 
islands. Yamazaki and colleagues (129) reported also did not 
detect changes in DNA methylation in CpG islands caused 
by TET mutations but instead detected hypermethylation at 
non-CpG islands. Rasmussen and colleagues recently reported 
that depletion of Tet2 in pre-leukemic hematopoietic cells 
in mice had little impact on the methylation status of CpG 
islands and promoters but rather led to progressive DNA 
hypermethylation at enhancer elements (130). While the failure 
to detect differential DNA methylation at CpG islands in the 
presence of TET2 mutations could be due to the degradation 
of mutant TET2 by IDAX as described above, this is at best 
speculative to date given the lack of direct evidence available. 
Finally, as the functional role of DNA methylation in non-CpG 
sites such as enhancers and gene bodies are largely unknown, 
how TET2 or IDH1/2 mutations lead to leukemia promoting 
transcriptional changes through hypermethylation in these sites 
is unclear; while TET2 was found to be significantly enriched 
with H3K4me1 and transcription factor p300 at the enhancer 
regions (131), whether TET2 is required for establishing these 
enhancers marks, whether mutant TET2 changes the behavior 
of these cis regulatory regions, and how this ultimately perturbs 
transcriptional networks is still unexplored.
DiSCUSSiON AND PeRSPeCTiveS
The high frequency of mutations in epigenetic regulators indi-
cates that epigenetic deregulation may play a critical role in the 
pathogenesis of certain myeloid malignancies. The finding of 
these mutations both in malignant cells of AML and MDS as well 
as within the phenotypically normal HSC of patients indicates 
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that these mutations may play a critical role in the pre-malignant 
phase of oncogenesis and evidence from single cell sequencing 
studies suggest that these cells can serve as reservoirs for disease 
relapse. In light of the increasing evidence for pre-LSC in both 
primary and relapse AML and in MDS, it is now critical to 
develop a more comprehensive understanding of what these cells 
are, how they are separated from other clones in CHIP, and how 
mutations in epigenetic regulators prime these pre-LSC toward 
oncogenesis. While a causal role for TET2 and DNMT3A muta-
tions is likely given that they are some of the most frequently 
mutated genes found in pre-LSC of AML and MDS patients, how 
exactly these mutations lead to leukemogenesis is still far from 
understood. For one, it is not clear how these mutations and their 
associated effects on global and local DNA methylation drive 
gene expression aberrations that impair normal hematopoiesis. 
Recent work has begun to shed some light on transcriptional 
and cell biological mechanisms that play a role in the formation 
of pre-LSC and their progression (132); however, it is unclear 
how exactly these transcriptional changes prime cells to become 
leukemic after acquisition of another genetic hit. The major 
limitation in answering these questions is technical: at present 
there exist no reliable cell surface markers that unambiguously 
separate pre-LSC from non-leukemic HSC clones. Therefore, 
deciphering the deregulated transcriptional programs occurring 
in pre-LSC, and how they relate to changes in DNA methylation 
cannot be readily achieved using ensemble approaches. Second, 
normal HSC are already documented as transcriptionally and 
functionally heterogeneous (133). As such, even single-cell 
gene expression technology like single-cell RNA-seq may only 
be adequate for identifying these transcriptional programs if 
single cell NGS or MeDIP-seq is performed concomitantly. 
At the time of writing, this technique has yet to be reported 
and is likely to represent an enormous technological challenge. 
Therefore, identifying what transcriptionally constitutes a truly 
“normal” versus “pre-leukemic” HSPC will be challenging given 
the present technology. Second, why certain mutations signifi-
cantly enrich with TET2 and DNMT3A is not well understood. 
One possibility is that loss of TET2 or DNMT3A specifically 
contributes to increased mutation rates at these cooperating 
hits. Another possibility is that these hits are randomly gener-
ated but are selectively able to complement TET2 or DNMT3A 
to drive leukemic evolution. As the clinical and biochemical 
implications of these two models differ significantly, establishing 
which contributes to AML and MDS is critical to developing a 
full understanding of these conditions and possibly developing 
novel therapeutics. In either case, however, the preponderance 
of these mutations in pre-LSC strongly suggests an important 
pathogenic role as leukemia initiation. Third, while the impor-
tance of DNA methylation in transcriptional regulation is well 
documented, a detailed mechanism of how DNA methylation 
patterns are established and maintained is far from complete. 
How these processes are locally augmented during normal 
hematopoietic differentiation is similarly unknown. The fact that 
multiple studies looking at loss of TET2 or DNMT3A reported 
similar phenotypic changes in HSC (namely GM skewed cell 
fate, increased self-renewal capacity, and global changes of DNA 
methylation status) seems to indicate that aberrant methylation 
patterns have robust effects on hematopoietic differentiation. 
The fact that hypo- and hyper-methylation patterns can have 
similar phenotypic consequences indicates that perhaps the 
marks per  se are not as important as the appropriate ratio of 
these marks across many local regions of the genome in the 
same cell. Further complicating matters is the finding that these 
methylation patterns do not appear to correlate well with gene 
expression changes in AML and MDS samples, while mutations 
in both TET2 and DNMT3A clearly have prognostic implications 
and participate in leukemogenesis. Given these points, decipher-
ing the language of these methylation patterns and determining 
how they dictate hematopoietic differentiation is a major focus 
of current research.
A substantial amount of research will be still required to fully 
understand how these epigenetic factors behave in both normal 
and malignant hematopoiesis. With technological advancements, 
particularly in NGS and single cell techniques, many of the coun-
terintuitive observations made regarding these enzymes may be 
elucidated. Given the inherent heterogeneity of normal HSPCs, 
it is quite likely that single cell transcriptomics and epigenomics 
may be ultimately required to fully understand how and when 
these factors become relevant in promoting LSC transformation. 
Despite the current technical limitations, however, the discovery 
of these mutations in pre-LSC has blossomed exciting new lines 
of research in both AML and MDS, diseases with classically 
poor prognoses and little therapeutic advances over the past few 
decades. Although it appears that the role epigenetic regulators 
play in leukemia initiation will be complex, those functions are 
likely to fundamentally alter current paradigms about how these 
myeloid malignancies develop and therefore may offer novel 
management avenues in the future.
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